Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Licensing deals morph to acquisitions in seller's market

Pharma's pipeline problems, coupled with the trend toward acquisition, are giving biotechs more leverage in licensing discussions.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

Authors

Related links

Related links

Related links in Nature Research

A reprise for collaborative financing in biotech

Pipeline cherrypicking deal yields lucrative return

Are small biotechs still underselling themselves?

Web links

BTG

SV Life Sciences

Ernst & Young

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moran, N. Licensing deals morph to acquisitions in seller's market. Nat Biotechnol 25, 609–610 (2007). https://doi.org/10.1038/nbt0607-609

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0607-609

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing